Quantcast
Last updated on April 18, 2014 at 7:49 EDT

Latest Ranbaxy Laboratories Inc. Stories

2012-11-26 08:25:01

PRINCETON, N.J., Nov. 26, 2012 /PRNewswire/ -- Ranbaxy Laboratories, Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced the sales and promotion launch of Absorica (Isotretinoin) Capsules, a product that is licensed from Cipher Pharmaceuticals Inc. of Mississauga, Ontario. Absorica is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. Due to its high lipophilicity, oral absorption of isotretinoin is...

2012-05-29 06:24:38

PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Cipher Pharmaceuticals Inc., RLI is expected to launch Absorica(TM) in the...

2012-05-28 02:20:52

Product to be launched as Absorica(TM)  Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.  Absorica is expected to be launched in the U.S. in Q4 2012. "Approval...

2012-05-27 18:20:10

Product to be launched as Absorica(TM)  Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica(TM), Cipher's novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.  Absorica is expected to be launched in the U.S. in Q4 2012. "Approval...